Ultragenyx Pharmaceutical Faces Class Action Lawsuit: Key Information for Investors
In recent developments, Ultragenyx Pharmaceutical Inc. has become the focus of a class action lawsuit, causing concern among its investors. The legal action is spearheaded by Kahn Swick & Foti, LLC, a respected law firm known for its work in securities litigation. Investors who suffered losses due to the company's alleged securities fraud between August 3, 2023, and December 26, 2025, are encouraged to take immediate action. The last date to apply to be a lead plaintiff in this case is April 6, 2026.
The lawsuit was prompted by a disclosure from Ultragenyx on December 26, 2025, regarding the failure of its Phase 3 clinical trials for setrusumab, a treatment aimed at osteogenesis imperfecta, commonly known as brittle bone disease. The company reported that the trials did not show a statistically significant reduction in fracture rates, leading to a plummet in the stock price—a drop of nearly 42% within a matter of days. This significant fall in share value, going from $34.19 to $19.72, has prompted investors to pursue legal recourse.
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is reaching out to affected investors. They emphasize the importance of acting swiftly if individuals have suffered losses as a result of the company's disclosures. Information about submitting a lead plaintiff application is readily available on their website.
The case is officially named Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., under docket No. 26-cv-01097. Importantly, potential claimants should know that even those who do not wish to serve as lead plaintiffs can still participate in any recovery that may arise from the case.
For those interested in learning more about the lawsuit or seeking representation, they can contact Lewis Kahn, Managing Partner at Kahn Swick & Foti, LLC, by phone at 1-877-515-1850 or email at [email protected]. Additionally, more information can be found through their official website.
Kahn Swick & Foti, LLC is recognized as one of the leading law firms in securities litigation, often ranked among the top firms nationally based on settlement values. They understand the needs of institutional and retail investors alike, aiding them in recovering losses from corporate malfeasance.
As the application deadline approaches, affected investors are urged not to miss this chance to reclaim their losses by getting in touch with the counsel promptly. The firm has established a strong presence, with offices in several states, confirming their capability to manage significant legal cases efficiently.
In conclusion, Ultragenyx investors should stay informed and proactive in the wake of this lawsuit. Whether voters are looking to recover losses or simply wish to understand their legal position, action must be taken before the deadline of April 6, 2026, to maximize their chances of a successful outcome in this ongoing legal battle.
The lawsuit was prompted by a disclosure from Ultragenyx on December 26, 2025, regarding the failure of its Phase 3 clinical trials for setrusumab, a treatment aimed at osteogenesis imperfecta, commonly known as brittle bone disease. The company reported that the trials did not show a statistically significant reduction in fracture rates, leading to a plummet in the stock price—a drop of nearly 42% within a matter of days. This significant fall in share value, going from $34.19 to $19.72, has prompted investors to pursue legal recourse.
Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is reaching out to affected investors. They emphasize the importance of acting swiftly if individuals have suffered losses as a result of the company's disclosures. Information about submitting a lead plaintiff application is readily available on their website.
The case is officially named Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., under docket No. 26-cv-01097. Importantly, potential claimants should know that even those who do not wish to serve as lead plaintiffs can still participate in any recovery that may arise from the case.
For those interested in learning more about the lawsuit or seeking representation, they can contact Lewis Kahn, Managing Partner at Kahn Swick & Foti, LLC, by phone at 1-877-515-1850 or email at [email protected]. Additionally, more information can be found through their official website.
Kahn Swick & Foti, LLC is recognized as one of the leading law firms in securities litigation, often ranked among the top firms nationally based on settlement values. They understand the needs of institutional and retail investors alike, aiding them in recovering losses from corporate malfeasance.
As the application deadline approaches, affected investors are urged not to miss this chance to reclaim their losses by getting in touch with the counsel promptly. The firm has established a strong presence, with offices in several states, confirming their capability to manage significant legal cases efficiently.
In conclusion, Ultragenyx investors should stay informed and proactive in the wake of this lawsuit. Whether voters are looking to recover losses or simply wish to understand their legal position, action must be taken before the deadline of April 6, 2026, to maximize their chances of a successful outcome in this ongoing legal battle.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.